With a market cap of $32.2 billion, IQVIA Holdings Inc. (IQV) is a leading global provider of advanced analytics, technology solutions, and clinical research services for the life sciences industry. Based in Durham, North Carolina, the company operates through four segments: Technology & Analytics Solutions, Research & Development Solutions, Contract Sales & Medical Solutions, and Contract Sales & Medical Solutions. Companies valued at $10 billion or more are generally classified as “large-cap” stocks, an ...

I rate IQVIA (NYSE: IQV ) with a buy rating. I am of the opinion that the company will generate value for its investors despite the U.S. President, Donald Trump, signing an executive order mandating drugmakers toDaniel Mellado is an economist from Carabobo University with a Master's Degree in Statistics from Simon Bolivar University, both obtained in Venezuela.Daniel worked analyzing the agricultural commodity market and the financial investment portfolio for an agribusiness group. Then, he managed two team ...

IQVIA Holdings Inc. (NYSE:IQV) is included in our list of the 14 Tech Stocks to Sell Now According to Ken Fisher. IQVIA Holdings Inc. (IQV) and Flagship Pioneering Partner to Accelerate Growth of Breakthrough Life Sciences Companies On August 28, 2025, IQVIA Holdings Inc. (NYSE:IQV) partnered with Flagship Pioneering to accelerate the creation and growth of breakthrough life sciences companies. This collaboration will offer Flagship’s biopharma ecosystem access to IQVIA Holdings Inc. (NYSE:IQV)’s extens ...

Financial Data and Key Metrics Changes - Total revenue for the quarter was $789 million, with non-GAAP operating income of $353 million, exceeding guidance [7] - The company raised its full-year billings guidance by $35 million, aligning with the revenue increase [16] Business Line Data and Key Metrics Changes - R&D subscriptions and services showed larger upside compared to previous models, indicating strong performance in this segment [20] - Commercial subscriptions remained flat quarter-over-quarter, with Crossix highlighted as a strong performer [72] Market Data and Key Metrics Changes - The resolution of the lawsuit with IQVIA is expected to unlock significant opportunities in the commercial area, enhancing product offerings and customer satisfaction [11][14] - The company has nine top 20 customers committed to Vault CRM, compared to three for Salesforce, indicating a strong competitive position [51] Company Strategy and Development Direction - The company is focusing on Veeva AI as a transformative element for both Veeva and the industry, with plans to monetize AI through industry-specific agents [7][27] - The resolution with IQVIA allows for greater integration of data into Veeva's products, enhancing the overall commercial suite [71] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving the $6 billion revenue target over the next five years, with no material changes expected in the quality segment [22] - The macro environment remains stable, with customers effectively navigating uncertainty and continuing to build pipelines [121] Other Important Information - The company is working on a platform-first approach for horizontal software, with CRM as the first application to be developed [63] - The integration of AI into the Vault platform is expected to create significant value for the industry over time, although material revenue contributions are not anticipated until 2026 or 2027 [29][30] Q&A Session Summary Question: Resolution of the lawsuit with IQVIA - Management noted that the resolution was due to changes in the industry and a mutual understanding that collaboration would benefit customers [11] Question: Confidence in billings guidance - Management indicated that annual billings are a better indicator of performance, and they are pleased with the increase in guidance [16] Question: Evolution of quality cloud - Management confirmed that quality cloud is receiving elevated focus and is expected to be a significant area of growth [20] Question: AI opportunities - Management discussed the potential for AI to enhance productivity and efficiency across various applications, with a focus on deep industry-specific agents [27][46] Question: Customer reaction to IQVIA resolution - Customer feedback has been overwhelmingly positive, with many exploring new possibilities for integration [34] Question: R&D subscription growth - Management attributed the growth to broad-based execution and a stable environment [40] Question: Resistance to change in Compass product suite - Management acknowledged some resistance but expressed confidence in overcoming these challenges as customers adapt [116]

Investment Rating - The report assigns a "Buy" rating to Thermo Fisher, while other companies such as Danaher, Samsung Bio, and Lonza remain unrated [2]. Core Insights - The report highlights that the impact of tariffs on the life sciences upstream sector is less than expected, leading to an overall upward revision of performance guidance for 2025 by most companies [4][29]. - Clinical CRO orders have unexpectedly increased, driven by strong biotech client demand, although the sustainability of this trend remains uncertain [4][31]. - The revenue recovery is outpacing profit recovery, with cost control pressures increasing due to external macroeconomic challenges [6][14]. Summary by Sections Performance Analysis - In 1H25, the performance of overseas CXO and life sciences upstream companies remained under pressure, but a sequential improvement was observed in 2Q25, with 7 out of 10 tracked companies showing revenue growth compared to 1Q25 [6][31]. - The median and average revenue growth rates for 2Q25 were +4.3% and +7.1%, respectively, compared to +0.2% and +6.0% in 1Q25, primarily driven by clinical CRO companies [6][8]. Tariff Impact - The impact of tariffs on sales of instruments and equipment for drug development and production was reported to be less than anticipated, with management from major life sciences companies indicating a more favorable outlook [29][30]. - Companies like Thermo Fisher and Danaher have adjusted their performance guidance upwards, reflecting a more optimistic view on tariff impacts [29][30]. Demand Trends - The C(D)MO sector continues to see strong commercial production demand, while life sciences upstream companies benefit from a recovery in consumable demand as clients complete inventory destocking [31][32]. - Clinical CRO demand has been bolstered by unexpected growth from biotech clients, although the sustainability of this demand is still in question [33][34]. Financial Metrics - The average gross margin for heavy asset companies decreased from 50.2% in 2021 to 45.7% in 2024, but showed signs of recovery in 2Q25 [15]. - The report notes that capital expenditures are expected to reverse the declining trend observed in 2023-24, potentially increasing future depreciation pressures [17]. Market Reactions - Following the release of 2Q25 results, stock prices for most overseas CXO and life sciences companies reacted positively, particularly for clinical CROs, which saw significant price increases due to better-than-expected performance [24][25].

人民财讯8月6日电，据科兴制药消息，近日，公司与IQVIA艾昆纬达成全面战略合作关系，双方将链接 彼此优势资源，共同推进科兴制药创新药和生物类似药在欧洲，乃至全球市场的临床设计、注册与商业 化进程。 ...

来源：ESG评级中心 点击查看更多企业ESG评级。 据新浪财经ESG评级中心，2025年07月29日，Iqvia Holdings Inc.（IQV.US）MSCI（明晟）ESG评级由 AA调升至AAA。 ...

Core Insights - The article emphasizes the importance of IQVIA Holdings' international operations in assessing its financial strength and growth potential [1][2] Revenue Performance - IQVIA's total revenue for the quarter ending June 2025 reached $4.02 billion, reflecting a 5.3% increase from the same quarter last year [4] - Revenue from Europe and Africa was $1.24 billion, accounting for 30.89% of total revenue, which was a decrease of 2.23% compared to Wall Street's expectations [5] - The Asia-Pacific region contributed $841 million, representing 20.94% of total revenue, exceeding analyst expectations by 4.89% [6] Future Projections - Analysts project IQVIA's total revenue for the current fiscal quarter to be $4.06 billion, indicating a 4.2% increase year-over-year [7] - For the entire year, total revenue is forecasted at $16.11 billion, a 4.6% improvement from the previous year, with Europe and Africa expected to contribute 32.1% and Asia-Pacific 20.4% [8] Market Dynamics - The reliance on international markets presents both opportunities and challenges for IQVIA, making the analysis of international revenue trends crucial for future forecasts [9][10] - The company's stock has increased by 26.5% over the past month, outperforming the S&P 500's 4.9% rise, indicating strong market performance [13]

IQVIA Holdings stock surged on Tuesday after the clinical research and analytics company's second-quarter results topped estimates. https://t.co/RpNKde2yOG ...

Group 1 - The article discusses IQVIA Holdings Inc.'s recent performance, highlighting a revenue of $3.83 billion in Q1, which was driven by growth in the Technology & Analytics Solutions (TAS) segment [1] - The author emphasizes the importance of innovative companies in the biotech and pharmaceutical sectors, particularly those developing breakthrough therapies with potential acquisition catalysts [1] Group 2 - The article is part of a subscription marketplace service called Compounding Healthcare, which offers model healthcare portfolios, a weekly newsletter, and a daily watchlist for investors [1]